Abstract
Histamine metabolite was prepared by incubating histamine dihydrochloride and diamino oxidase for 24 h at 37°C. Radioactive histamine was used for monitoring the whole procedure and to select the best experimental protocol. Pharmacological activities of histamine are abolished by this procedure. Histamine metabolite was found to bind to the serum proteins, to inhibit the PHA response of mouse and human mononuclear cells and to accelerate mortality rates in tumor-bearing mice. Thin layer chromatography allowed separation of metabolite from histamine and from known imidazol-derived compounds. This is the first experimental evidence for immunological properties ascribed to a histamine metabolite.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
